EXPRESSION PROFILE OF miR-145, -182, -21, -27a, -29b, and -34a IN BREAST CANCER PATIENTS OF YOUNG AGE

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Breast cancer (BC) in young women is a significant public health concern.
• Identifying prognostic biomarkers is crucial for tailoring treatment and improving outcomes.
• MicroRNAs (miRs) are increasingly recognized as potential biomarkers in various cancers.

Purpose of the Study:

• To investigate the association between tumor-associated microRNA expression and the clinical-pathological features of breast cancer in young patients.
• To explore the potential of specific miRs as prognostic indicators for BC in women under 45.

Main Methods:

• Analysis of miR-145, -182, -21, -27a, -29b, and -34a expression in tumor samples from 50 young BC patients (stage I-II).
• Real-time reverse transcription polymerase chain reaction (RT-PCR) was used for quantification.
• Correlation of miR expression with tumor stage, lymph node metastasis, and molecular subtypes.

Main Results:

• Higher expression of miR-182, -21, and -29b, and lower miR-27a levels were linked to tumor stage.
• Patients without lymph node metastasis (N0) showed higher miR-182, -27a, -34a and lower miR-29b compared to N1 cases.
• Expression patterns of miR-145, -182, -21, -27a, and -29b correlated with distinct molecular BC subtypes.

Conclusions:

• Elevated miR-182, -21, -29b, and -34a, along with decreased miR-27a, are associated with higher malignancy in young women's BC.
• These microRNAs show promise as predictive biomarkers for breast cancer aggressiveness in younger populations.
• Further research can validate these findings for clinical application in personalized BC treatment.